SWK Holdings is a specialty finance company focused on providing debt and royalty financing to small commercial-stage life science companies. SWK's core product is the first lien term loan, typically secured by a borrower's royalty streams, revenue interests, or other cash flows. SWK also purchases royalties outright or creates synthetic revenue interests. Borrowers are typically companies commercializing drugs, medical devices, diagnostics, life science tools, or animal health products. SWK targets transactions in the sub-$50M range — particularly $10M–$25M — where it faces less competition from larger lenders. Since launching this strategy in 2012, SWK has deployed approximately $876M across 58 life science counterparties. SWK earns money primarily through interest and fees on its loan portfolio, which carries an effective yield of roughly 14%–15%, along with royalty and revenue interest payments tied to product sales. Many deals also include warrants or contingent payments that represent additional upside. SWK recently sold its MOD3 Pharma CDMO subsidiary, making the Finance Receivables segment its sole business. The remaining portfolio consists of approximately $234M in gross performing first lien term loans, plus small equity and warrant positions. SWK operates with just 9 employees, and management's focus is on disciplined underwriting, targeting loan-to-value below 40%, and growing book value per share rather than rapid portfolio expansion. Excess capital is returned to shareholders via buybacks and special dividends.